Nephrotic syndrome is a classic clinical constellation characterized by structural injury to the glomerular filtration barrier, resulting in massive urinary protein loss, profound oncotic fluid shifts, and systemic metabolic derangements 3, 5. Imagine looking through a high-powered electron microscope at the kidney's filtering units: the delicate, interdigitating 'foot processes' of the visceral epithelial cells—the podocytes—have flattened and fused together, destroying the negative charge barrier that normally keeps serum proteins safely inside the circulation 4, 7. On the ward, this manifests as a dramatic triad (or tetrad): heavy proteinuria exceeding 3.5 grams per 24 hours, severe hypoalbuminaemia under 25–30 g/L, and pitting generalized oedema that often starts around the eyes in the morning and settles in the lower extremities by evening 3, 5, 7. Understanding this syndrome requires mastering its complex downstream consequences, from hypercoagulability caused by urinary loss of antithrombin III to secondary hyperlipidaemia driven by hepatic lipoprotein synthesis 4.

1. Etiology & Risk Factors

  • Primary (Idiopathic) Glomerular Diseases: Includes Minimal Change Disease (MCD)—the paramount cause in children 2, 6; Focal Segmental Glomerulosclerosis (FSGS), common in adults and frequently linked to maladaptive hyperfiltration or genetic mutations 3; Membranous Nephropathy (MN), strongly associated with anti-phospholipase A2 receptor (PLA2R) antibodies in adults 3; and Membranoproliferative Glomerulonephritis (MPGN) 5.
  • Secondary Systemic Pathologies: Diabetic nephropathy (the leading cause of nephrotic-range proteinuria in Western populations) 3, systemic lupus erythematosus (SLE / lupus nephritis Class V) 6, amyloidosis (demonstrating apple-green birefringence on Congo red staining), and paraproteinaemias like multiple myeloma 5.
  • Infectious & Malignant Triggers: Chronic viral infections (Hepatitis B, Hepatitis C, HIV), syphilis, post-infectious glomerulonephritis, and solid-organ malignancies (carcinomas linked to membranous nephropathy) or lymphomas (Hodgkin lymphoma classically linked to minimal change disease) 5.
  • Pharmacological & Genetic Factors: Use of non-steroidal anti-inflammatory drugs (NSAIDs) or penicillamine; inherited podocin, nephrin, or alpha-actinin-4 gene mutations underlying steroid-resistant congenital or familial nephrotic syndromes 2, 6.

2. Pathophysiology

The core pathogenetic event in nephrotic syndrome is the loss of integrity in the multi-layered glomerular filtration barrier, which is composed of the fenestrated endothelial glycocalyx, the complex glomerular basement membrane (GBM), and the slit diaphragm spanning adjacent podocyte foot processes 4, 7. Under normal physiological conditions, this barrier restricts molecules larger than albumin based on both molecular size and negative charge (heparan sulfate polyanions). When circulating immune complexes, circulating permeability factors (such as suPAR in FSGS), or metabolic insults damage the podocytes, actin cytoskeletal reorganization occurs, resulting in widespread podocyte foot process effacement 2, 7.

The consequent massive filtration of plasma proteins overwhelms the reabsorptive capacity of the proximal convoluted tubules. The resulting hypoalbuminaemia decreases plasma oncotic pressure (Starling forces), drawing fluid out of the intravascular space into the interstitial compartments, clinically presenting as generalized oedema 4, 5. Simultaneously, the underfilled arterial circulation triggers compensatory renal retention of sodium and water via activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. In parallel, the liver responds to falling serum oncotic pressure and lipid clearance defects by upregulating hepatic synthesis of lipoproteins and coagulation factors (e.g., fibrinogen, factors V, VIII, and X), while simultaneously losing anticoagulant proteins like antithrombin III and plasminogen in the urine, setting the stage for a severe hypercoagulable state and hyperlipidaemia 4.

Nephrotic syndrome — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Immune-mediated podocyte injury, genetic mutations, or diabetic metabolic stress 2 Cellular / Pathophysiological Cascade Effacement of podocyte foot processes and degradation of the glomerular basement membrane 3 Target Organ / Structural Change Loss of electrostatic and size selectivity of the glomerular filtration barrier 4 Hallmark Clinical & Diagnostic Manifestation Massive urinary protein loss leading to serum hypoalbuminaemia and oncotic fluid shifts 5 Complications if Untreated & Therapeutic Target Hypercoagulability, infection risk, progressive tubulointerstitial fibrosis, and renal failure

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients typically report progressive, painless swelling that is initially periorbital upon waking and evolves into dependent pitting pedal or scrotal/labial oedema 3, 7. Severe intravascular volume depletion can cause fatigue, lethargy, abdominal pain (due to bowel oedema or primary peritonitis), and oliguria 5, 7. Frothy urine—caused by lowered surface tension from heavy proteinuria—is a classic patient-reported observation.
  • Physical Examination & Named Clinical Signs: Generalized pitting oedema leaving indentations over the shins and sacrum; pleural effusions and ascites upon chest and abdominal percussion/auscultation; and occasionally signs of underlying systemic disease such as malar rashes (SLE) or peripheral neuropathy (amyloidosis) 3, 6.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationUltrasound-guided percutaneous renal biopsy in adults (essential for identifying histological sub-types via light microscopy, immunofluorescence, and electron microscopy) 3.
Laboratory PanelSpot urine protein-to-creatinine ratio (PCR) greater than 300–350 mg/mmol (or 24-hour urine protein >3.5 g); serum albumin less than 25–30 g/L; hypercholesterolaemia and hypertriglyceridaemia; normal or elevated serum creatinine depending on acute kidney injury status 3, 7.
Imaging / Radiology (X-ray, US, CT, MR)Renal ultrasound showing normal-sized or enlarged kidneys (suggesting acute or infiltrative pathology like diabetes or amyloidosis) or small, echogenic kidneys (chronic scarring); chest X-ray confirming pleural effusions.
ECG / Histopathology / ProceduralUrine microscopy revealing fatty casts, oval fat bodies showing 'Maltese cross' birefringence under polarized light, and microscopic haematuria in certain glomerulonephritides 3.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Steroid Response (Paediatric)Steroid-Sensitive (remission achieved within 4 weeks of standard prednisolone therapy) vs. Steroid-Resistant (persistent proteinuria despite 8 weeks of therapy, prompting genetic testing and calcineurin inhibitors) 2, 6.
Histopathological ClassificationPrimary glomerulopathies (Minimal Change Disease, Focal Segmental Glomerulosclerosis, Membranous Nephropathy) vs. Secondary systemic manifestations (Diabetic Nephropathy, Amyloidosis, Lupus Nephritis) 3, 5.
Proteinuria SeverityNephrotic-range proteinuria defined as greater than 3.5 g/24h (or urine protein-to-creatinine ratio >300 mg/mmol), dictating high risk for thrombotic and infectious complications 3, 7.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Cirrhosis / Liver FailureOedema accompanied by spider angiomata, palmar erythema, deranged clotting (PT/INR), and low synthetic liver function tests with normal or mildly elevated urine protein.
Congestive Heart FailureElevated JVP, cardiomegaly on chest radiography, elevated BNP/NT-proBNP, and history of cardiac disease with non-nephrotic proteinuria.
Severe Protein-Losing EnteropathyGastrointestinal symptoms (diarrhoea), normal urinary protein excretion, and low serum alpha-1 antitrypsin clearance.
Nephritic SyndromeCharacterized by prominent active urinary sediment (red blood cell casts, dysmorphic RBCs), hypertension, and acute kidney injury with sub-nephrotic proteinuria.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Assess intravascular volume status carefully. Avoid aggressive diuresis in patients with severe hypovolaemia or impending acute kidney injury; manage electrolyte imbalances (especially hyponatraemia and hypokalaemia) 3, 4.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Dietary & Symptomatic: Dietary sodium restriction (< 2 g/day) and loop diuretics (e.g., oral Furosemide 40 mg to 80 mg daily, titrated up to 250 mg twice daily if diuretic resistance occurs due to low tubular drug delivery) 3.
    • Antiproteinuric Agents: ACE inhibitors (e.g., Lisinopril 10 mg PO daily, titrated to max 40 mg) or ARBs (e.g., Losartan 50 mg PO daily, titrated to max 100 mg) to reduce intraglomerular capillary pressure 3.
    • Thromboembolic Prophylaxis: Prophylactic low-molecular-weight heparin (e.g., Enoxaparin 40 mg SC daily) or oral anticoagulation when serum albumin drops below 20–25 g/L, particularly in Membranous Nephropathy 3, 7.
    • Lipid Lowering: Statins (e.g., Atorvastatin 20–40 mg PO daily) to manage hypercholesterolaemia and reduce cardiovascular risk 3.
  • Disease-Specific Immunosuppression:
    • Minimal Change Disease: Oral Prednisolone at 1 mg/kg/day (maximum 80 mg daily) for 4–8 weeks, followed by a slow taper 2, 6.
    • Membranous Nephropathy: Anti-PLA2R monitoring, combined with Rituximab or Calcineurin inhibitors (e.g., Tacrolimus) based on risk stratification 3.
  • Surgical / Interventional Indications: Ultrasound-guided percutaneous renal biopsy for tissue diagnosis in adults with unexplained nephrotic syndrome before initiating cytotoxic or immunosuppressive regimens 3.

8. Complications & Prognosis

  • Thromboembolic Events: Hypercoagulability secondary to urinary loss of antithrombin III and hepatic overproduction of procoagulant factors predisposes patients to renal vein thrombosis, deep vein thrombosis, and pulmonary embolism 4, 7.
  • Infectious Complications: Urinary loss of immunoglobulins (IgG) and complement factor B increases susceptibility to encapsulated organisms, predisposing to spontaneous bacterial peritonitis and cellulitis 4, 6.
  • Acute Kidney Injury (AKI): Can occur secondary to profound intravascular volume depletion ("praerenal azotemia"), acute tubular necrosis, or bilateral renal vein thrombosis 4, 7.
  • Chronic Renal Failure & Prognosis: While Minimal Change Disease generally preserves long-term renal function with excellent steroid responsiveness, untreated FSGS and membranous nephropathy carry a significant risk of progression to end-stage renal disease (ESRD) requiring renal replacement therapy 2, 3, 6.